• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.72 EUR+0.93 %14.8, 17.29
5,669 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+0.93 %
+2.42 %
+5.65 %
-16.92 %
-31.55 %
-34.32 %
+173.80 %
+78.02 %
-98.39 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
78.49M EUR
Turnover
146.37K EUR
P/E (adj.) (26e)
77.82
EV/EBIT (adj.) (26e)
63.15
P/B (26e)
7.68
EV/S (26e)
6
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
14.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
January–June 2026 Summary The company’s revenue was 5.2 million euros (4.5), an increase of 16.1% Revenue growth adjusted for currency exchange effects was 17.7% Equipment sales were 1.9 million euros (2.2), a decrease of 12.4%. Recurring revenue accounted for 2.5 million euros (...
yesterday
by bullero22
26
Nexstim published its long-term financial targets for the first time: • Average annual revenue growth of over 20%. • Operating profit margin of over 20%.
yesterday
by Ledificazione
23
It seems that we need something extra for it to really take off. For example, 10-20 more for Brainlab, or strong in-house sales, a new move in a new direction, or perhaps clear evidence of the advantages of Nexstim’s device in BCI research. Right now, it feels like everyone wants...
yesterday
by Jatast
16
Nexstim H1’26: Strong growth driven by Sinaptica license fees - Inderes Nexstim H1'26: Vahvaa kasvua Sinaptican lisenssimaksujen vetämänä - Inderes In that interview, Mikko says that Nexstim shook hands on its last proprietary deals on the diagnostics side during H1. This likely ...
yesterday
by Fin Master
14
That 0.7 million from Brainlab was interesting, considering that 0.1 million was recognized from the warranty provision last year. So, the sales targets were not met in H1. Of course, that doesn’t matter as long as they get sales moving in the future. I wonder what the H1 vs. H2 ...
yesterday
by Jatast
11
Another link for you In my opinion, a solid, basic performance just as expected. Inderes NEXSTIM OYJ:N PUOLIVUOSIKATSAUS 1.1.–30.6.2026 (TILINTARKASTAMATON) - Inderes Yhtiötiedote, Helsinki, 14.8.2026 klo 9.00 (EEST)NEXSTIM OYJ:N PUOLIVUOSIKATSAUS 1.1.–30.6.2026 (TILINTARKASTAMATON...
yesterday
by TemeMOME
11
Hi, I had assumed 1 million from Sinaptica for H2, so on an annual basis, we are roughly in line with the assumptions. However, it was not assumed for H1, and the top-line beat is explained by this Sinaptica payment. It was indeed factored in, but clearly on the low side.
yesterday
by Antti Siltanen
7
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release14.08.2026, 08.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026, 08.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026, 08.25 by
Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release31.07.2026, 12.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026, 12.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026, 08.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026, 08.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026, 08.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026, 08.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026, 08.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release07.07.2026, 08.00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim
New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026, 08.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026, 08.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release11.06.2026, 08.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment04.06.2026, 07.48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release03.06.2026, 09.00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release25.05.2026, 08.00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release18.05.2026, 16.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim